Get the Stockscreener App
56.59
3.22%
-1.88
Travere Therapeutics Inc stock is traded at $56.59, with a volume of 1.25M.
It is down -3.22% in the last 24 hours and up +21.07% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
See More
Previous Close:
$58.47
Open:
$58
24h Volume:
1.25M
Relative Volume:
0.51
Market Cap:
$5.26B
Revenue:
$536.20M
Net Income/Loss:
$-45.64M
P/E Ratio:
-105.82
EPS:
-0.5348
Net Cash Flow:
$-28.94M
1W Performance:
-0.58%
1M Performance:
+21.07%
6M Performance:
+63.65%
1Y Performance:
+241.93%
1-Day Range:
$55.00
$58.48
1-Week Range:
$55.00
$59.69
52-Week Range:
$15.03
$60.10
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
56.59 | 5.26B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-31-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics Accounting Chief Sandra Calvin to Retire in 2027 - Moomoo
Why (TVTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Travere Therapeutics, Inc. Files Form 8-K with SEC: Key Details on Company and Stock Listing for July 2026 - Minichart
Sandra Calvin to Retire as Travere Therapeutics CAO; John Torell Named Successor - TradingView
Travere Therapeutics (NASDAQ: TVTX) plans CAO transition as Sandra Calvin retires - Stock Titan
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Travere Therapeutics Inc. (TVTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
US FDA approves Vera's kidney disease drug - Reuters
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib - Macau Business
Travere Therapeutics, Inc. Actuals & Estimates (NASDAQ:TVTX) - TradingView
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy - AOL.com
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress - AOL.com
Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative? - simplywall.st
Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics Receives Notice of Allowance from the U.S. P - The National Law Review
Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Understanding Momentum Shifts in (TVTX) - Stock Traders Daily
Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Enterprise value to revenue forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Price to earnings forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Thera - The National Law Review
Price to sales forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
TVTX Maintained by Guggenheim -- Price Target Raised to $65 - GuruFocus
TVTX Forecast — Price Target — Prediction for 2027 - TradingView
Travere Therapeutics stock hits 52-week high at 56.9 USD By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 56.9 USD - Investing.com
Travere Therapeutics Inc (TVTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Travere Therapeutics Inc (TVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Travere Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Travere Therapeutics (NASDAQ: TVTX) CMO gifts 468 shares in Form 4 - Stock Titan
TVTX Maintains by Wedbush -- Price Target Raised to $61.00 - GuruFocus
Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says - marketscreener.com
Travere and Everest Medicines Strike $1.1 Billion Rare Kidney Disease Deal - The Healthcare Technology Report.
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $49 to $67 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):